This study’s aim was to explore relationships between preterm infant behavioral outcomes and maternal/infant glucocorticoid (dexamethasone [DEX]) treatments using a psychoneuroimmunologic approach. Research questions were (a) do relationships exist between infant cumulative perinatal steroid (PNS) exposure and child behavioral problems? and (b) do maternal/infant characteristics (e.g., immune markers and biophysiologic stressors) influence these relationships?
Methods:
The convenience sample comprised 45 mother–child dyads in which the children (mean age 8 years ± 2.3) had been born at a mean postconceptional age of 28 weeks (± 4.2). We used the Child Behavior Checklist (CBCL) to assess behavior, the Clinical Risk Index for Babies (CRIB) to score stress at birth, and retrospective record review to identify additional perinatal factors (PNS dosage, sepsis, and maternal and infant complete blood counts near delivery).
Results:
Children were dichotomized into high (> 0.2mg/kg; n = 20) versus low–no (≤0.2 mg/kg; n = 25) PNS exposure groups. Significant relationships existed between CBCL Total Problems score and sepsis, PNS exposure, timing of initial PNS, and infant length percentile at discharge. Competence problems were significantly associated with PNS, neonatal intensive care unit (NICU) infant length percentile, CRIB score, sepsis, retinopathy of prematurity, hearing deficit, and immunity markers (i.e., maternal lymphocyte percentage and infant band/seg ratio). Children in the higher PNS group exhibited more behavioral problems (e.g., withdrawn, attention, conduct, social, and rule breaking problems), but there were no significant differences. The findings are reassuring regarding long-term effects of this PNS dose on preterm infant behavioral outcomes.
AchenbachT.RuffleT. (2001). The child behavior checklist and related forms for assessing behavioral/emotional problems and competencies. Pediatrics in Review, 21, 265–271.
American Academy of Pediatrics, Committee on Fetus and Newborn & the Canadian Paediatric Society, Fetus and Newborn Committee. (2002). Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics, 109, 330–338.
4.
BallardP.BallardR. (1995). Scientific basis and therapeutic regimens for use of antenatal glucocorticoids. American Journal of Obstetrics and Gynecology, 181, 709–717.
5.
BarringtonK. J. (2001). The adverse neuro-developmental effects of postnatal steroids in the preterm infant: A systematic review of RCTs. BMC Pediatrics, 1, 1.
6.
BenesovaO.PavlikA. (1989). Perinatal treatment with glucocorticoids and the risk of maldevelopment of the brain. Neuropharmacology, 28, 89–97.
7.
BosA.DibiasiJ.TiessenA.BergmanK. (2002). Treating preterm infants at risk for chronic lung disease with dexamethasone leads to an impaired quality of general movements. Biology of the Neonate, 82, 155–158.
8.
BrazyJ.EckermanC.OehlerJ.GoldsteinR.O’RandA. (1991). Nursery neurobiologic risk score: Important factors in predicting outcome in very low birth weight infants. Journal of Pediatrics, 118, 783–792.
9.
CoeC.LubachG. (2000). Prenatal influences on neuroimmune set points in infancy. Annals of the New York Academy of Sciences, 917, 468–477.
10.
CoeC.LubachG. (2005). Prenatal origins of individual variation in behavior and immunity. Neuroscience and Biobehavioral Reviews, 29, 39–49.
11.
CrowtherC. A.DoyleL. W.HaslamR. R.HillerJ. E.HardingJ. E.RobinsonJ. S.,for the ACTORDS Study Group. (2007). Outcomes at 2 years of age after repeat doses of antenatal corticosteroids. New England Journal of Medicine, 357, 1179–1189.
12.
DarunaJ. H. (2004). Introduction to psychoneuroimmunology. San Diego, CA: Elsevier.
13.
DoyleL.DavisP. (2000). Postnatal corticosteroids in preterm infants: Systematic review of effects on mortality and motor function. Journal of Paediatric Child Health, 36, 101–107.
14.
DoyleL.FordG.RickardsA.KellyA.DavisN.CallananC. (2000). Antenatal corticosteriods and outcome at 14 years of age in children with birth weight less than 1501 grams [Abstract]. Pediatrics, 106, e2.
15.
DunlapS.ArcherM.QuinlivanJ.BeazleyL.NewnhamJ. (1997). Repeated prenatal corticosteroids delay myelination in the ovine central nervous system. Journal of Maternal and Fetal Medicine, 6, 309–313.
16.
EsplinM.FausettM.SmithS. (2000). Multiple courses of antenatal steroids are associated with delay in long-term psychomotor development in children with birth weights ≤ 1500 grams. American Journal of Obstetrics and Gynecology, 182, S24.
17.
FleckB.McIntoshN. (2009). Retinopathy of prematurity. Recent developments. NeoReviews, 10, 20–30.
18.
FrenchN.HaganR.EvansS.GodfreyM.NewnhamJ. (1999). Repeated antenatal corticosteroids: Size at birth and subsequent development. American Journal of Obstetrics and Gynecology, 180, 114–121.
19.
GagliardiL.CavazzaA.BrunelliA.BattaglioliMMerzziD.TandoiF.…BelluR. (2004). Assessing mortality risk in very low birthweight infants: A comparison of CRIB, CRIB-II, and SNAPPE-II. Archives of Disease in Children, Fetal Neonatal Edition, 89, F419–F422.
HackM.FlanneryD.SchluchterM.CartarL.BorawskiE.KleinN. (2002). Outcomes of young adulthood for very-low-birth-weight infants. New England Journal of Medicine, 346, 149–157.
22.
HallidayH. L.EhrenkranzR. A. (2001a). Delayed (> 3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants [online]. Cochrane Database of Systematic Reviews, 2, CD001145.
23.
HallidayH. L.EhrenkranzR. A. (2001b). Early postnatal (< 96 hours) corticosteroids for preventing chronic lung disease in preterm infants [online]. Cochrane Database of Systematic Reviews, 1, CD001146.
24.
HilleE.den OudenA.SaigalS.WolkeD.LambertM.WhitakerA.…FeldmanJ. (2001). Behavioural problems in children who weigh 1000 g or less at birth in four countries. Lancet, 357, 1641–1643.
25.
JobeA.IkegamiM. (2000). Beyond the NIH consensus conference for antenatal glucocorticoids. Neonatal Respiratory Diseases, 10, 1–8.
26.
KopelmanA.MoiseA.HolbertD.HegemierS. (1999). A single very early dexamethasone dose improves respiratory and cardiovascular adaptation in preterm infants. Journal of Pediatrics, 135, 345–350.
27.
LefebvreF.GrégoireM.DuboisJ.GlorieuxJ. (1998). Nursery neurobiologic risk score and outcome at 18 months. Acta Paediatrica, 87, 751–757.
28.
LigginsG.HowieR. (1972). A controlled trial of antepartum glucocorticoid treatment for prevention of respiratory distress syndrome in premature infants. Pediatrics, 50, 515–525.
29.
LodhaA.SauvéRChenS.TangS.ChristiansonH. (2009). Clinical risk index for babies score for the prediction of neurodevelopmental outcomes at 3 years of age in infants of very low birthweight. Developmental Medicine and Child Neurology, 51, 895–900.
30.
MasonW.KosermanR.HawkinsJ.HerrenkohlT.LenguaL.McCauleyE. (2004). Predicting depression, social phobia, and violence in early adulthood from child behavior problems. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 307.
MatthewsS. G. (2001). Antenatal glucocorticoids and the developing brain: Mechanisms of action. Seminars in Neonatology, 6, 309–317.
33.
MattiaF.deRegnierA. (1998). Chronic physiologic instability is associated with neurodevelopmental morbidity at one and two years in extremely premature infants. Pediatrics, 102, 1–14. doi:10.1542/peds.102.3.e35
34.
MossT. J.HardingR.NewnhamJ. P. (2002). Lung function, arterial pressure and growth in sheep during early postnatal life following single and repeated prenatal corticosteroid treatments. Early Human Development, 66, 11–24.
35.
National Institute of Health. (1994). Consensus development conference statement. Effect of corticosteroids for fetal maturation on perinatal outcomes, February 28–March 2, 1994. American Journal of Obstetrics and Gynecology, 173, 246–252.
36.
National Institutes of Health. (2000). Report of the consensus development conference on antenatal corticosteroids revisited: Repeat courses. Bethesda, Maryland: National Institute of Child Health and Human Development.
37.
NgP.WongG.LamC.LeeC.FokT.WongM.MaK. (1999). Effect of multiple courses of antenatal corticosteroids on pituitary-adrenal function in preterm infants. Archives of Disease in the Child, Fetal and Neonatal Edition, 80, F213–F216.
38.
OwenD.AndrewsM.MatthewsS. (2005). Maternal adversity, glucocorticoids and the programming of neuroendocrine function and behavior. Neuroscience and Biobehavioral Reviews, 29, 209–226.
39.
PeabodyJ. (2000). Interpreting risks of steroids for preterm infants. Journal of Pediatrics, 137, 590–592.
40.
PerlmanJ. M. (2001). Neurobehavioral deficits in premature graduates of intensive care—Potential medical and neonatal environmental risk factors. Pediatrics, 108, 1339–1348.
41.
PiecuchR.LeonardC.CooperB.SehringS. (1997). Outcome of extremely low birth weight infants (500 to 999 grams) over a 12-year period. Pediatrics, 100, 633–639.
42.
PurdyI. B.SmithL. M.WileyD.HowesC.GawlinskiA.RobbinsW.BadrL. (2008). Cumulative perinatal steroids: Child development of preterm infants. Journal of Pediatric Nursing, 23, 210–214.
43.
RichardsonD.CorcoranJ.EscobarG.LeeS. (2001). SNAP-II and SNAPPE-II: Simplified newborn illness severity and mortality risk scores. Journal of Pediatrics, 138, 92–100.
44.
SaigalS.PinelliJ.HoutlL.KimM.BoyleM. (2003). Psychopathology and social competencies of adolescents who were extremely low birth weight. Pediatrics, 111, 969–975.
45.
ShoenerJ.BaigR.PageK. (2006). Prenatal exposure to dexamethasone alters hippocampal drive on hypothalamic-pituitary-adrenal axis activity in adult male rats. American Journal of Physiology—Regulatory, Integrative and Comparative Physiology, 290, R1366–R1373.
46.
SlotkinT.KreiderM.TateM.SeidlerF. (2006). Critical prenatal and postnatal periods for persistent effects of dexamethasone on serotonergic and dopaminergic systems. Neuropsychopharmacology, 31, 904–911.
47.
SmolkinT.SteinbergM.SujovP.MezerE.TamirA.MakhoulI. (2008). Late postnatal systemic steroids predispose to retinopathy of prematurity in very-low-birth-weight infants: A comparative study. Acta Paediatrica, 97, 322–326.
48.
SparrowS.BallaD.CicchettiD. (1984). Vineland adaptive behavior scales survey form manual. Circle Pines, MN: American Guidance Incorporated.
49.
StarkA.CarloW.TysonJ.PapileL.WrightL.ShankaranS.…StevensonD.,for the National Institute of Child Health Human Development Neonatal Research Network (2001). Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. New England Journal of Medicine, 344, 95–101.
50.
StollB. J.GordonT.KoronesS. B. (1996). Early-onset sepsis in very low birth weight neonates: A report from the National Institute of Child Health and Human Development Neonatal Research Network. Journal of Pediatrics, 129, 63–80.
51.
WalshM.YaoQ.HorbarJ.CarpenterJ.LeeS.OhlssonA. (2006). Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks. Pediatrics, 118, 1328–1335.
52.
YehT. F.LinY. J.LinH. C.HuangC. C.HsiehW. S.LinC. H.TsaiC. H. (2004). Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. New England Journal of Medicine, 350, 1304–1313.
